RxDoctor Payments Data

Bradley Secrest, MD

Urology · Hattiesburg, MSNPI 1306955950

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,712 of the $8,670 with a category attached, or 65.9%. 43 manufacturers reported payments, led by Axonics, Inc. at 42.1% of the total. Reporting peaked in 2022 at $2,397 and has fallen 56.8% since, to $1,036 in 2025.

$8,670in general payments, 2019–2025

Across 273 payments — averaging $31.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$4K
  • Neotract Inc.$741
  • Johnson & Johnson$467
  • Dendreon Pharmaceuticals LLC$348
  • Coloplast$333
  • Sumitomo Pharma America, Inc.$322
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$2,95834%
  • Food & beverage$5,71266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,670 in reported general payments places this provider in the 85th percentile of 94 urology providers in Mississippi.

See all urology providers in Mississippi

Medicare billing

Part B allowed, 2024
$450,600
Medicare patients
1,111
Services billed
58,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron151$103,071
GemtesaVibegron125$95,667
Tamsulosin Hcl1,706$25,726
Trospium Chloride130$5,816
Finasteride381$5,529
NitrofurantoinNitrofurantoin Macrocrystal154$5,069
Bethanechol Chloride85$5,024
Trimethoprim62$4,228
Alfuzosin Hcl ErAlfuzosin Hcl275$3,906
Ciprofloxacin Hcl490$3,128
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst206$3,119
Methenamine Hippurate39$2,643
Imipramine Hcl121$2,534
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav155$1,987
Testosterone Cypionate44$1,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$313$103,071151 claims
Sumitomo Pharma America, Inc.Gemtesa$322$95,667125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 94 urology providers in Mississippi.

Other urology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →